TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
IRVINE, Calif., June 17, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a securities class action lawsuit against Amyris, Inc. (“Amyris” or the “Company”) (Nasdaq:AMRS). Investors who purchased or otherwise acquired shares between March 2, 2017 and April 17, 2017 inclusive (the “Class Period”), are encouraged to contact the Firm by the June 19, 2017 lead plaintiff motion deadline.
If you purchased Amyris shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Amyris made false and/or misleading statements and/or failed to disclose: that in the first quarter of 2017, the Company made a decision to take an equity stake in one of Blue California’s affiliates that focused on the sweetener market instead of cash payment under the license agreement; that due to this decision Amyris would be unable to recognize $10 million in fourth quarter and fiscal year 2016 revenue from the license agreement with Blue California; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news reached the public, Amyris’ share price dropped materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, Esquire, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or via e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
